PHARMACEUTICAL INDUSTRY EXPANSION INTO BROADER HEALTH SECTORS LIKELY TO FACE LESS OVERSIGHT UNDER REPUBLICANS: BEGINNING OF ERA OF HEALTH CARE REFORGING?
Glaxo's $5 mil. loan/investment in asthma clinics through Circadian, Inc. and J&J's agreement with the Nutri/System weight loss clinics are harbingers of the type of vertical merger activity that should accelerate throughout the health care field and particularly in the drug business with the Republican Congress virtually controlling antitrust oversight during the next two years.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth